Summary:
Symbiotec Pharmalab IPO was subscribed 4.75 times by Day 3, led by strong NII demand at 10.59 times. Retail investors subscribed 4.62 times, while employee participation reached 5.42 times and QIB bidding stood at 0.59 times. With the issue closing on August 27, institutional participation will be crucial for the final subscription tally.
Symbiotec Pharmalab, the Indore-based pharmaceutical and biotechnology company, saw subscription build further on Day 3 of its ₹1,757 crore mainboard IPO, with overall demand reaching 4.75 times as of the update on August 26, 2026.
IPO Details
| Detail | Information |
| Issue Size | ₹1,757 crore (fresh issue ₹150 crore + OFS ₹1,607 crore) |
| Price Band | ₹938–₹988 per share |
| Lot Size | 15 shares |
| Minimum Investment (Retail) | ₹14,820 |
| Face Value | ₹2 per share |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Registrar | MUFG Intime India Pvt Ltd |
| Book-Running Lead Managers | JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, Nomura Financial Advisory |
Category-wise Breakdown on Day 3
| Category | Shares Offered/Reserved | Shares Bid For | Subscription (x) |
| Qualified Institutional Buyers (QIBs) | 37,39,872 | 21,95,385 | 0.59 |
| Non Institutional Investors | 28,04,904 | 2,97,09,090 | 10.59 |
| — NII (bids above ₹10 lakh) | 18,69,936 | 1,82,24,565 | 9.75 |
| — NII (bids ₹2–10 lakh) | 9,34,968 | 1,14,84,525 | 12.28 |
| Retail Individual Investors (RIIs) | 65,44,778 | 3,02,61,135 | 4.62 |
| Employees | 35,377 | 1,91,810 | 5.42 |
| Total | 1,31,24,929 | 8,23,57,220 | 4.75 |
Data as of 26-Aug-2026, 3:24 PM IST, sourced from NSE Consolidated Bid Details (nseindia.com).
Symbiotec Pharmalab IPO - Day 3 Subscription Status
As of the update on August 26, 2026, the issue received bids for 8,23,57,220 shares against 1,31,24,929 shares on offer, taking overall subscription to 4.75 times. Non-Institutional Investors led the demand at 10.59 times, followed by Employees at 5.42 times and Retail Individual Investors at 4.62 times, while Qualified Institutional Buyers stayed below full subscription at 0.59 times.
What Day 3 Numbers Indicate
Subscription climbing from 1.85 times on Day 2 to 4.75 times by Day 3 shows steady, continued demand building across NII, employee, and retail categories. Within the NII category, the ₹2–10 lakh bracket (12.28x) continues to outpace the above-₹10-lakh bracket (9.75x), suggesting smaller HNIs remain more aggressive bidders than larger applicants through this stage of the issue. With QIB bidding still below the 1x mark, institutional demand — which typically surges only in the final session of mainboard issues — will be the key factor determining the overall subscription level by close on August 27.
Symbiotec Pharmalab IPO - Timetable
| Event | Date |
| Anchor Bid Date | August 21, 2026 |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Allotment Finalisation | August 28, 2026 |
| Refund/Demat Credit | August 31, 2026 |
| Listing Date | September 1, 2026 |
| Listing Exchanges | BSE, NSE |
Should You Apply for Symbiotec Pharmalab IPO?
Incorporated in 2002 and headquartered in Indore, Symbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology, and complex injectables. The company's business spans corticosteroid and steroidal-hormone active pharmaceutical ingredients, along with nutritional ingredients and specialty products, serving both domestic and international regulated and emerging markets. Revenue grew 15% year-on-year to ₹872.26 crore in FY26, with profit after tax rising 14% to ₹109.90 crore.
Investors considering the issue should weigh the company's specialised API capabilities, steady revenue and profit growth, and exposure to regulated international markets against risks typical of the pharmaceutical API business, such as regulatory compliance requirements across geographies and pricing pressure in commoditised segments. As with any IPO, the decision should be based on individual risk appetite, investment horizon, and a review of the RHP rather than subscription numbers alone.
How to Apply for Symbiotec Pharmalab IPO
Investors can apply for the Symbiotec Pharmalab IPO through ASBA via their bank's net banking portal, via UPI-based ASBA through their stock broker's trading app, or offline by submitting a physical ASBA form through their broker. The minimum lot size is 15 shares, requiring a minimum investment of approximately ₹14,820 at the upper price band.
How to Check Symbiotec Pharmalab IPO Subscription Status
How to check Symbiotec Pharmalab IPO Subscription Status on NSE website
- Visit the NSE IPO issue information page (nseindia.com).
- Search for "Symbiotec Pharmalab" or enter the symbol SYMBIOTEC.
- Select "Consolidated Bid Details" from the dropdown to view category-wise subscription data.
- The page refreshes periodically to show live bidding figures during market hours.
How to check Symbiotec Pharmalab IPO Subscription Status on BSE website
- Visit the BSE IPO page (bseindia.com).
- Navigate to the "Active IPO" or "IPO Bidding" section.
- Select "Symbiotec Pharmalab Limited" from the list of active issues.
- View category-wise and overall subscription figures, updated through the bidding window.
How to check Symbiotec Pharmalab IPO Subscription Status on Ventura?
Ventura clients can track real-time subscription status for the Symbiotec Pharmalab IPO directly within the IPO section of the Ventura app or web platform, alongside category-wise bid data and allotment updates — without needing to switch between exchange websites.
IPO Subscription History
Previous Day Subscription
Subscription rose from 0.80 times on Day 1 to 1.85 times on Day 2, with Employees and Non-Institutional Investors leading demand while QIB bidding stayed comparatively muted throughout.
Conclusion
Symbiotec Pharmalab's IPO continues to build steadily heading into its final day, with overall subscription reaching 4.75 times on the back of consistent NII, employee, and retail participation. With bidding closing on August 27, institutional demand will be the key factor to watch, as QIB bidding typically sees a sharp final-day surge in mainboard issues.
